Peptide Half-Life Chart
What the Published Data Actually Shows
A cautious reference for approved and studied peptides. Half-life varies by formulation, route, and study design, so use this as a starting point rather than a dosing rule.
How To Read A Half-Life Chart
Half-life is a pharmacokinetic estimate, not a guarantee of effect duration. Route of administration, albumin binding, and formulation can change it materially.
For many research peptides, publicly available human PK data are limited or absent. If you cannot verify a label or primary study, treat the number as provisional rather than prescriptive.
Examples With Published Data
Semaglutide
~1 week
FDA labeling reports an elimination half-life of approximately one week.
Tirzepatide
~5 days
FDA labeling reports an elimination half-life of about five days.
CJC-1295
Long-acting
Primary studies show prolonged GH and IGF-1 activity after subcutaneous administration.
Research peptides
Verify first
If a label or primary study is missing, do not assume a confident human half-life.
How To Use The Chart Safely
Start with the product label or primary study, not a social-media summary.
Separate the half-life of the molecule from the duration of the effect you are trying to measure.
Check the route and formulation before comparing two peptides side by side.
Use the chart as a reference for tracking, not as a substitute for prescribing guidance.
Why This Matters In Shotlee
When you log the dose, site, and timing of each injection in Shotlee, you can compare real-world response against the published timing window rather than relying on memory.
That makes it easier to spot whether a product is behaving like its label suggests or whether the formulation, route, or schedule needs to be reviewed with a clinician.
Guide FAQs
Not exactly. Half-life is a useful starting point, but the clinical effect can be longer or shorter depending on route, formulation, and downstream biology.
Only as a rough guide. If you cannot trace the number to a label or a primary study, treat it as provisional.
References
- [1]FDAOZEMPIC (semaglutide) prescribing information. U.S. Food and Drug Administration.
- [2]FDAMOUNJARO (tirzepatide) prescribing information. U.S. Food and Drug Administration.
- [3]Clinical TrialJetter A et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006.
- [4]Clinical TrialTeichman SL et al. Activation of the GH/IGF-1 axis by CJC-1295 in normal adult subjects. J Clin Endocrinol Metab. 2006.
Track Your Peptide Half-Life Reference In Shotlee
Free dose logging, side effect tracking, and timing notes for your protocol.
🚀 Use Shotlee for Free